NeuroOne's StereoCED™ Platform Aims to Streamline Brain Drug Delivery

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has released a new white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” highlighting its innovative drug delivery platform designed to overcome key barriers in delivering brain therapeutics. The white paper, available on the Scientific Resources section of www.nmtc1.com or by clicking here, addresses the growing demand for efficient methods to deliver cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics directly to the brain. While convection-enhanced delivery (CED) can bypass the blood-brain barrier, current approaches often involve lengthy procedures lasting 8 to 12 hours, which could hinder commercial scalability.

The StereoCED™ platform leverages robotic stereotactic systems already common in neurosurgical operating rooms, enabling simultaneous, multi-trajectory intracranial drug delivery through a streamlined workflow. This approach is designed to significantly reduce procedure time and support reproducible, scalable therapeutic delivery. The platform is currently under development and has not yet been cleared by the FDA. Dave Rosa, President and CEO of NeuroOne, emphasized that as brain-delivered therapeutics approach commercialization, healthcare systems will need solutions that integrate with existing workflows, reduce procedure time, and enable scalable delivery across hospitals. Device availability for research and investigational clinical studies is expected by fiscal year-end.

NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. Its existing product families include Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System, all FDA-cleared. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation. The white paper underscores NeuroOne's commitment to advancing CNS drug delivery and addressing the bottlenecks that could limit the commercial adoption of promising brain therapies.